Drug Companies Step Up 'Make in America' Plans to Counter Tariffs
In This Article:
Drugmakers Roche and Regeneron said they will spend billions of dollars to expand U.S. manufacturing, the latest pharmaceutical companies to commit to American production as new and future tariffs loom over medicines made abroad. Regeneron, which makes drugs for skin and respiratory diseases, is doubling its U.S. manufacturing capacity in a new $3 billion, 10-year agreement with Fujifilm Diosynth Biotechnologies. Fujifilm’s plant in Holly Springs, N.C., will make bulk drug material for Regeneron medicines.
Terms and Privacy Policy